Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

Catawba Research Announces the Promotion of Andrew Silverman, Ph.D., to CEO


Catawba Research, a leading clinical research organization with a goal to become the world's most trusted CRO, is announcing changes to its executive leadership team. Effective today, Catawba's Founder, Zaidoon A. Al-Zubaidy, is transitioning his day-to-day leadership responsibilities to Dr. Andy Silverman. Al-Zubaidy will become executive chairman where he will support customer relationships and provide mentorship to the executive leadership team. Silverman will expand his responsibilities from operational leadership as chief operating officer (COO) to driving the entire organization to meet its growth targets as the chief executive officer (CEO).

Silverman was recruited to Catawba by Liberty Lane Partners because of his extensive background in clinical research built off a 30-year career with PPD, INC Research and Syneos Health. "Since joining the firm in early 2022, Andy has exceeded our expectations at every step. He has been instrumental in establishing market leading operational capabilities at Catawba that have positioned the company for its next phase of growth. His leadership has made an impact on all stakeholders and given us confidence that he will succeed in his expanded role," said Nick Goldstein, managing director of Liberty Lane Partners.

"I am honored to be appointed CEO of Catawba Research," said Silverman. "Building on the remarkable foundation that Zaidoon and our dedicated team have established, we will continue our mission to drive innovation in clinical research and deliver agile solutions across an evolving portfolio of therapeutic areas to our clients and partners."

As Executive Chairman, Al-Zubaidy will ensure Catawba maintains its dedication to its core values as it grows. "I am extremely proud of Catawba Research's accomplishments since our founding in 2014. And I look forward to serving as a mentor and partner to our seasoned executive team as we pursue our next leg of growth," said Al-Zubaidy. "While I'll be stepping away from day-to-day operations, I will make sure Catawba remains an agile, responsive and trusted partner to our sponsors. I am extremely confident with Andy's leadership and vision, we will continue our outstanding history of delivering excellence in clinical research services."

Please join us on this journey and wish Andy the best of luck in his new role.

About Catawba Research

Catawba Research is a leading contract research organization specializing in clinical research and development services for the pharmaceutical, biotechnology, and medical device industries. With a strong commitment to quality, innovation, and client satisfaction, Catawba Research delivers comprehensive solutions to advance healthcare products from concept to market. For more information, please visit www.catawbaresearch.com.


These press releases may also interest you

at 14:20
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...



News published on and distributed by: